达格列净治疗糖尿病合并消化性溃疡的价值研究
Study on the Value of Dapagliflozin in the Treatment of Diabetes Mellitus Combined with Peptic Ulcer
林秋龙 1陈学淳1
作者信息
- 1. 闽侯县人民医院内科,福建福州 350119
- 折叠
摘要
目的 分析达格列净治疗糖尿病合并消化性溃疡的价值.方法 选取2022年9月—2023年8月闽侯县人民医院收治的86例糖尿病合并消化性溃疡患者为研究对象,采用随机数表法分为两组,各43例.对照组使用二甲双胍片治疗,研究组在对照组基础上联合达格列净治疗.对比两组血糖指标水平、临床疗效、不良事件发生情况、生活质量.结果 治疗后,研究组血糖指标、临床疗效、生活质量均优于对照组,差异有统计学意义(P均<0.05).两组不良事件发生率对比,差异无统计学意义(P>0.05).结论 达格列净治疗糖尿病合并消化性溃疡,能够降低血糖水平,提高疗效与生活质量,且安全性较高.
Abstract
Objective To analyze the value of dapagliflozin in the treatment of diabetes mellitus combined with peptic ulcer.Methods A total of 86 patients with diabetes mellitus combined with peptic ulcer admitted to Minhou County People's Hospital from September 2022 to August 2023 were selected as the study objects and were divided into two groups with 43 cases in each group by the random number table method.The control group used metformin tablets,and the study group combined with dapagliflozin on the basis of the control group.Blood glucose indexes,clinical effi-cacy,adverse events and quality of life of the two groups were compared.Results After treatment,the study group had better blood glucose indexes,clinical efficacy,and quality of life compared with the control group,and the differences were statistically significant(all P<0.05).There was no statistically significant difference in the incidence of adverse events between the two groups(P>0.05).Conclusion Dapagliflozin in the treatment of diabetes mellitus combined with peptic ulcer can reduce blood glucose level,improve efficacy and quality of life,and is safe.
关键词
达格列净/糖尿病/消化性溃疡/疗效/血糖/不良事件Key words
Dapagliflozin/Diabetes mellitus/Peptic ulcer/Therapeutic efficacy/Blood glucose/Adverse events引用本文复制引用
出版年
2024
NETL
NSTL
万方数据